Dr. Meisel On Optimizing Genomic Assays In Early-Stage Hr-Positive, Her2-Negative Breast Cancer

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. Soliman

Total Health | Oncology

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer

Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast Cancer

Targeted Oncology

Jane Meisel, MD | Advice on Metastatic Breast Cancer at 2019 ASCO Direct Highlights St. Louis

Total Health | Oncology

Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...

Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...

Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer

Dr. Meisel on Emerging Treatment Strategies in TNBC

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. Schwartzberg

Total Health | Oncology

Utilizing Genomic Assays for Decision Making in Early Stage Breast Cancer

Targeted Oncology

Dr. Simon on Genomic Assays for Patients With Breast Cancer

Adjuvant Treatment for Early Stage Hormone Positive Breast Cancer: Role of Genomic Signatures

Total Health | Oncology

Genomic Assays Impact Treatment Decisions in Patients With ER+ Breast Cancer

Targeted Oncology

2021 MDONS | The Nurses Role in Early Stage Breast Cancer | A Focus on Genomic Assays

Total Health | Oncology

OLD VID 1

Dr. Brufsky on Genomic Assays for Breast Cancer

Genomic Testing for Risk of Late Recurrence/ASCO Guidelines

Dr. Graff on Genomic Risk Prediction in HR+/HER2- Breast Cancer

2021 Best of Breast | Case 1 Genomic Testing

Total Health | Oncology